EBMT 2019 | NGS: a valuable tool for elucidating the genetic landscape of AML

Torsten Haferlach

Torsten Haferlach, MD, of Munich Leukemia Laboratory, Munich, Germany, discusses how next-generation sequencing (NGS) can significantly facilitate the uncovering of genetic mutations associated with acute myeloid leukemia (AML). Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Prof. Haferlach reports that NGS can enable scientists to gain important information for diagnosis, prognostication and measurable residual disease (MRD) in the context of AML.

Share this video